CNBC
19 Nov 2026, 08:33 UTC · 15h ago
Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031
Impact · against what's priced in
Novartis shares react negatively to a slight reduction in long-term growth guidance and the confirmation of a 2031 patent cliff for Kisqali. While the $4 billion increase in peak sales forecasts for three blockbusters provides a revenue cushion, it does not fully offset the lowered annual growth ceiling of 5%.
- NOVN+0.10
No priced-in read yet
- In context
The upward revision of combined peak sales to $18 billion for Kesimpta, Scemblix, and Leqvio is positive, but it is tempered by a revised annual sales growth forecast of 5% and a confirmed generic entry for Kisqali in H2 2031.
Read from the article alone

Search tags




